Ensysce Executive Agreement Amended
Ensysce Biosciences amended Dr. Lynn Kirkpatrick's employment and title to Chief Operating Officer effective January 1, 2027. Market relevance is null as no financial guidance was issued.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed